儿童神经源性逼尿肌过度活动所致尿失禁的膀胱内电动力肉毒毒素A长期随访
本研究纳入24例脊髓脊膜膨出患儿,平均年龄9±3.6岁,随访6年,评估膀胱内电动力肉毒毒素A(BoNTA-EMDA)的长期疗效。一次治疗后,完全干燥率在1、2、3、5、6年分别为75%、45.5%、37.5%、33%、29.1%。最大逼尿肌压显著下降,最大膀胱测压容量显著增加(P<.05)。
要点
- 一次BoNTA-EMDA治疗后6年,29.1%患儿在两次清洁间歇导尿间完全干燥。
- 随访中各时点最大逼尿肌压显著下降、最大膀胱测压容量显著增加(P<.05)。
- BoNTA-EMDA为门诊无麻醉操作,原文称其可行、安全、可重复、成本效益好、持久且无痛。
核心结论
- BoNTA-EMDA是门诊无麻醉、无膀胱镜操作下可行、安全、可重复、成本效益好、持久且无痛的方法,对难治性NDO患儿的尿失禁和尿动力学参数有相当改善。
研究设计与样本
- 研究纳入24例脊髓脊膜膨出患儿(平均年龄9±3.6岁,范围3-16岁),随访6年。
主要发现
- 一次BoNTA-EMDA治疗后,完全干燥率在随访1、2、3、5、6年分别为18/24(75%)、11/24(45.5%)、9/24(37.5%)、8/24(33%)、7/24(29.1%)。
- 随访中平均最大逼尿肌压显著下降,平均最大膀胱测压容量显著增加(P<.05)。
关键数值与推荐
- 使用电极膀胱导管,以10 IU/kg的Dysport(BoNTA)行EMDA,门诊无麻醉操作。
- EMDA设备连接留置导管电极和2个分散电极,脉冲电流发生器输出10 mA持续20分钟。
- 初步评估包括排尿日记、尿动力学检查、肾脏和膀胱超声,并每年复查。
临床怎么用
- 对脊髓脊膜膨出相关NDO所致尿失禁患儿,可考虑门诊无麻醉下行BoNTA-EMDA治疗。
- 治疗前及每年应进行排尿日记、尿动力学检查和肾脏膀胱超声评估。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the long-term efficacy and success rate of intravesical electromotive botulinum toxin type A (BoNTA) "Dysport" administration in patients with myelomeningocele who had urinary incontinence due to neuropathic detrusor overactivity (NDO). MATERIALS AND METHODS: Twenty-four patients with myelomeningocele (mean age: 9 ± 3.6 years, range: 3-16) were included in the study and followed up for 6 years. Using an electrode bladder catheter, 10 IU/kg of Dysport (BoNTA) was inserted into the bladder for electromotive drug administration (EMDA) without anesthesia on outpatient basis. The EMDA equipment was connected to the electrode of an indwelling catheter and 2 dispersive electrodes, and a pulsed current generator delivered 10 mA for 20 minutes. The preliminary assessments were voiding diary, urodynamic study, kidney and bladder ultrasounds which were also performed annually. RESULTS: Prior to the treatment, all patients had NDO and urinary incontinence. During the follow-up, 18 of 24 (75%), 11 of 24 (45.5%), 9 of 24 (37.5%), 8 of 24 (33%), and 7 of 24 (29.1%) of the patients were completely dry between 2 consecutive clean intermittent catheterizations after once BoNTA-EMDA treatment at 1, 2, 3, 5, and 6 years of follow-up, respectively. The mean maximum detrusor pressure significantly decreased and mean maximal cystometric capacity significantly increased at follow-ups (P <.05). CONCLUSION: The results of the present study have shown that BoNTA-EMDA is a feasible, safe, reproducible, cost-effective, long-lasting, and pain free method on an outpatient basis, with long-term duration of effects without anesthesia or cystoscopy procedure. This novel delivery system resulted in considerable improvement in urinary incontinence and urodynamic study parameters in patients with refractory NDO.
引用
- Ladi-Seyedian SS, Sharifi-Rad L, Kajbafzadeh AM, et al. Intravesical Electromotive Botulinum Toxin Type "A" Administration for Management of Urinary Incontinence Secondary to Neuropathic Detrusor Overactivity in Children: Long-term Follow-up. Urology. 2017. PMID: 29229221. doi:10.1016/j.urology.2017.11.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。